Caroline Phillips

Caroline has extensive experience in drug discovery and early clinical development. She has been instrumental in the development of Redx’s oncology pipeline, including progressing Redx’s lead oncology asset, RXC004, a potential best-in-class, orally bioavailable porcupine inhibitor into two Phase 1 studies and signing a research collaboration with Jazz Pharmaceuticals for two targeted cancer therapies.